Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects both people and
animals and may cause significant respiratory problems, including lung illness: Corona …

SARS-CoV-2 infection is not like the seasonal flu. While the range of symptoms for the two
viruses is similar, the fraction with severe disease appears to be different. For COVID-19 …

Background Evidence links COVID-19 severity to hyper-inflammation. Treatment with
tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was …

Introduction IFN-α intervention may block SARS-CoV-2 replication and normalize the
deregulated innate immunity of COVID-19. Aim This meta-analysis aimed to investigate the …

Background We systematically reviewed the literature to answer the following research
questions:(1) Does interleukin 6 (IL-6)(receptor) antagonist therapy reduce mortality in …

Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19). The
World Health Organization (WHO) therefore endorses supportive care only. However …

Introduction: The coronavirus disease 2019 (COVID-19) caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed since December 2019. It …

Objectives To the best of our knowledge, there is no published study regarding use of IFN β-
1a in the treatment of severe COVID-19. In this randomized clinical trial efficacy and safety of …

The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …